HMN Financial Inc
Change company Symbol lookup
Select an option...
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
Go

Financials : Thrifts & Mortgage Finance | Small Cap Value
Company profile

HMN Financial, Inc. (HMN) is a stock savings bank holding company that owns Home Federal Savings Bank (the Bank). The Bank operates retail banking and loan production facilities in Minnesota, Iowa and Wisconsin. The Bank has two subsidiaries, Osterud Insurance Agency, Inc., which offers financial planning products and services, and HFSB Property Holdings, LLC, which acts as an intermediary for the Bank in holding and operating certain foreclosed properties. HMN's business involves attracting deposits from the general public and businesses and using such deposits to originate or purchase one- to four-family residential, commercial real estate and multi-family mortgage loans, among others. HMN invests in mortgage-backed and related securities, the United States government agency obligations and other permissible investments. HMN serves the southern Minnesota counties of Dodge, Fillmore, Freeborn, Houston, Mower, Olmsted and Winona, and portions of Steele, Goodhue and Wabasha.

Closing Price
$13.40
Day's Change
0.10 (0.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.40
Day's Low
13.40
Volume
(Heavy Day)
Volume:
2,276

10-day average volume:
2,733
2,276

Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest for $1.25 billion

8:43 am ET July 21, 2020 (MarketWatch)
Print

Gilead Sciences Inc. (GILD) announced Tuesday a deal to buy a 49.9% stake in privately held cancer treatment developer Tizona Therapeutics Inc. for $300 million. Gilead also received an option to buy the remainder of Tizona for up to an additional $1.25 billion, including potential future milestone payments. The option to buy the rest of Tizona can be exercised before, or following, the readout of a Phase 1b study of Tizona's investigational TTX-080 to treat tumors. The Food and Drug Administration has cleared TTX-080's investigation drug application, and Tizona plans to initiate a Phase 1 trial in the third quarter. "Tizona is pursuing first-in-class cancer immunotherapies that could make an important difference in oncology by helping patients who don't respond to current checkpoint inhibitors," said Gilead Chief Executive Daniel O'Day. Gilead's stock, which slipped 0.4% in premarket trading, has rallied 20.2% year to date through Monday, while the iShares Nasdaq Biotechnology ETF (IBB) has advanced 21.0% and the S&P 500 has edged up 0.7%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 21, 2020 08:43 ET (12:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.